^
BIOMARKER:

JAK2 mutation

i
Other names: JTK10, THCYT3, JAK2, Janus Kinase 2, Tyrosine-Protein Kinase JAK2, JAK-2
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
Phase 1/2
M.D. Anderson Cancer Center
Completed
Last update posted :
08/15/2022
Initiation :
02/12/2015
Primary completion :
03/19/2021
Completion :
03/19/2021
JAK2
|
JAK2 mutation
|
Jakafi (ruxolitinib) • azacitidine • decitabine
Phase 2
Incyte Corporation
Recruiting
Last update posted :
08/15/2022
Initiation :
09/30/2016
Primary completion :
09/29/2025
Completion :
09/29/2025
JAK2 • CRLF2 • JAK1 • IL7R • EPOR • SH2B3
|
CRLF2 rearrangement • IL7R mutation • JAK2 mutation • JAK2 fusion • SH2B3 deletion
|
cytarabine • Jakafi (ruxolitinib) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Erwinase (erwinia L-asparaginase) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1b/2
Kartos Therapeutics, Inc.
Recruiting
Last update posted :
08/04/2022
Initiation :
09/25/2019
Primary completion :
12/15/2023
Completion :
07/15/2024
IDH1 • IDH2
|
JAK2 mutation
|
cytarabine • decitabine • navtemadlin (KRT-232) • Depocyte (liposomal cytarabine) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
06/10/2022
Initiation :
07/01/2011
Primary completion :
07/01/2023
Completion :
07/01/2023
JAK2 • CD4
|
JAK2 mutation
|
zelavespib intravenous (PU-H71 IV)
Phase 1
Rutgers, The State University of New Jersey
Recruiting
Last update posted :
05/17/2022
Initiation :
10/26/2020
Primary completion :
04/30/2024
Completion :
04/30/2024
TP53 • NPM1 • JAK2 • RUNX1 • ASXL1
|
TP53 mutation • FLT3-ITD mutation • RUNX1 mutation • ASXL1 mutation • RAS mutation • JAK2 mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
William Shomali
Recruiting
Last update posted :
11/19/2021
Initiation :
11/15/2019
Primary completion :
04/21/2023
Completion :
10/21/2023
JAK2 • ETV6 • PCM1
|
JAK2 mutation • JAK2 rearrangement
|
Jakafi (ruxolitinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
University of Chicago
Recruiting
Last update posted :
09/16/2021
Initiation :
05/28/2019
Primary completion :
09/05/2022
Completion :
09/05/2024
JAK2 • CRLF2 • IL7R • SH2B3
|
CRLF2 rearrangement • IL7R mutation • JAK2 mutation • JAK2 rearrangement • SH2B3 deletion
|
Rituxan (rituximab) • cytarabine • Jakafi (ruxolitinib) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Ciusss de L'Est de l'Île de Montréal
Recruiting
Last update posted :
08/09/2021
Initiation :
04/01/2019
Primary completion :
12/01/2023
Completion :
12/01/2023
TP53 • FLT3 • JAK2 • CD34 • HLA-DRB1
|
TP53 mutation • FLT3 mutation • RAS mutation • JAK2 mutation
|
cyclophosphamide • ECT-001-CB • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
M.D. Anderson Cancer Center
Completed
Last update posted :
04/15/2019
Initiation :
02/01/2014
Primary completion :
04/02/2019
Completion :
04/02/2019
JAK2 • NFKB1
|
JAK2 mutation
|
Jakafi (ruxolitinib)